ArticleClinical and translational radiation oncology2026
Pneumonitis after chemoradiotherapy and/or immunotherapy for stage III and IV non-small cell lung cancer is characterized by specific radiologic and quantitative CT features.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with unresectable stage III non-small cell lung cancer (NSCLC) receive a combination of chemotherapy (CT), thoracic radiation therapy (RT) and immune checkpoint inhibition (ICI). Stage IV NSCLC with a high PD-L1 tumor proportion score receive first line treatment with ICI. These new therapies and combinations can give rise to pneumonitis due to RT but also due to ICI, both etiologies being notoriously difficult to disentangle. In this work follow-up CT scans with pneumonitis after these treatments were explored in a radiologic pattern and a quantitative CT feature analysis. Materials and methods: This retrospective, single-center study included patients with pneumonitis of any grade who received chemoradiotherapy with or without durvalumab (RT-only group and RT + ICI group) for unresectable stage III NSCLC between 2011 and 2021, as well as patients with pneumonitis who received pembrolizumab as first-line therapy (ICI-only group) for stage IV NSCLC between 2017 and 2021. Clinical data and computed tomography (CT) scans were collected at baseline and follow-up. A radiologist compared CT characteristics among the three groups to identify patterns of radiotherapy-related and ICI-related pneumonitis. Furthermore, quantitative imaging features of lung damage derived from follow-up CT scans were compared between different lung regions within the same patient and across treatment groups. Results: Seventy-one patients developed pneumonitis: 36/163 in the RT-only group (22.1%), 18/116 in the ICI-only group (15.5%), and 17/36 in the RT + ICI group (47.2%, Conclusion: A significantly higher incidence of pneumonitis was observed in patients treated with combined RT and ICI. High-grade pneumonitis was more often bilateral, presented with distinct radiologic patterns, developed earlier, and was associated with pre-existing ILD and reduced diffusion capacity. Quantitative CT analysis confirmed that the combination of moderate- to high-dose lung irradiation with ICI therapy leads to greater severity of lung damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.